Incytevs.Vertex Pharmaceuticals
INCY vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 5.2× larger than Incyte by market cap; Incyte trades at the lower P/E (16.1 vs 27.9); year to date, Incyte leads (+18.2% vs +7.1%).
Side by side
| INCY | VRTX | |
|---|---|---|
| Market cap | $23.1B | $121B |
| Price | $116.71 | $485.39 |
| Today | −1.5% | −2.2% |
| Return YTD | +18.2% | +7.1% |
| Return 1Y | +65.9% | +1.2% |
| P/E | 16.1 | 27.9 |
| P/S | 4.3 | 9.9 |
| P/B | 4.1 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where INCY and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →